Navigation Links
Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
Date:9/5/2007

IRVINE, Calif., Sept. 5 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, today announced that it has received CE Mark approval for European commercial sales of its Edwards SAPIEN transcatheter aortic heart valve technology with the RetroFlex transfemoral delivery system.

The Edwards SAPIEN transcatheter heart valve is implanted via a minimally-invasive procedure, without requiring open-heart surgery. It is the first transcatheter bovine pericardial valve incorporating technological advancements and design elements that allow for greater ease of implantation by physicians. The valve is designed to treat patients with severe aortic heart valve stenosis (a narrowing of the valve that restricts blood flow), who are considered to be high-risk or non-operable for conventional open-heart valve replacement surgery.

"This is a landmark achievement for this transformational technology, which holds promise for the large number of high-risk patients suffering from severe aortic stenosis," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO. "As the global leader in heart valve therapy, we are committed to working closely with our European clinical partners on this transcatheter technology, in order to provide optimal clinical outcomes for the many high-risk patients in need of aortic valve replacements, who might otherwise have limited or no treatment options."

"In this pioneering procedure, the skill sets of the surgeon and the interventional cardiologist complement each other to provide for better patient care," said Martin B. Leon, MD, Professor of Medicine and Associate Director of the Center for Interventional Vascular Therap
'/>"/>

SOURCE Edwards Lifesciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Doctors Hopeful for Elizabeth Edwards
2. Infant receives first bloodless liver transplant
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. British MPs Say Prostate Cancer Receives Low Priority in the NHS
6. Abbott Receives CE Mark Certification
7. Zactima Receives Fast Track Designation By The FDA
8. East London Receives World Class New Private Hospital Facility
9. Brinda Karat Receives Legal Notice over Ramdev Issue
10. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
11. Medtronic’s Insulin Pump Receives Regulatory Approva
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008).../PRNewswire-FirstCall/ -- Cepheid (Nasdaq:,CPHD) t...ntract with,Premier, Inc., one of the largest U.S....han 1,500 participating hospitals and 42,000 other...ent, Cepheid has also,signed a preferred vendor ag...work (WNCHN), a collaboration of 53 acute care hos...
(Date:5/12/2008)...PRNewswire-USNewswire/ -- The American,Veterinary ...on castration,and dehorning of cattle to provide v... pain associated with these procedures. The revise...tate that practitioners use any,particular method ...me,basic recommendations for consideration by prac...
(Date:5/12/2008)... of Pay-for-Performance Programs , At a time whe...this study finds that while such programs may succ...physician income, they also change the nature of p...s work together. In-depth interviews with 41 famil...dom three years after implementation of a new pay-...
(Date:5/11/2008)...e Fatally Injured; No Patient was On-Board, DENVE...rporation,(Nasdaq: AIRM ), reported today that on...e University of Wisconsin Hospitals and Clinics in...10:30 p.m. CST after,delivering a patient to a hos...se received fatal injuries. The wreckage was found...
Breaking Medicine News(10 mins):Health News:Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations 2Health News:Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations 3Health News:Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations 4Health News:Revised AVMA Policy on Castrating and Dehorning Cattle Provides Additional Guidance for Managing Pain 2Health News:May/June 2008 Annals of Family Medicine tip sheet 2Health News:May/June 2008 Annals of Family Medicine tip sheet 3Health News:May/June 2008 Annals of Family Medicine tip sheet 4Health News:May/June 2008 Annals of Family Medicine tip sheet 5Health News:May/June 2008 Annals of Family Medicine tip sheet 6
...pecies with unpaired electrons have been implicate...ancer. The scientific community has been trying ha... free radicals by supplementation with anti-oxidan...radicals. // Anti-oxidants are abundant in fruits ...
... been a quest regarding the treatment of AIDS/HIV ...e the initiation of a global research, AIDS still ...imately five percent of patients with HIV, or huma...op AIDS, or do so very slowly.// Past research su...
...h team led by Professor Claudio Soto from the Univ...rion’ proteins behind such diseases in the blood o... the proteins that cause Mad Cow disease, raising ... form of the condition, Creutzfeldt-Jackobson dise...
... are often the ones who make fewer visits to the d...appens in spite of the fact that smoking puts them...s.// The finding holds true regardless of age, ge...cioeconomic status, location and insurance coverag...
Other Medicine News:Health News:Study holds promise for new way to fight HIV 2Health News:Blood Test To Detect Creutzfeldt-Jakob Disease/Mad Cow Disease 2
(Date:5/8/2008)...Treatment Provides "Blueprint" to Produce Therapeu...Ill., May 8 /PRNewswire-USNewswire/ -- Using gene,...ghting proteins through,skin flaps placed on cance... tumor volume, according to a study in the May iss...fficial medical journal of the American,Society of...
(Date:5/8/2008)...ther Data Presentations to Focus on Use of Pro-Hea...ot Tolerate Dual-Antiplatelet Therapy, HONG KONG,... from both,a randomized pilot study and the real-w...eered R stent, the world,s first pro-healing stent...roPCR 2008 in Barcelona, Spain., The symposium, t...
(Date:5/8/2008)...tch Formulation May Provide New Option for Clinici...e When Using an Oral NSAID, TAMPA, Fla., May 8 /P...),a leading global specialty pharmaceutical compa...ed this week at the American Pain Society annual,m...positive pharmacokinetic,profile of Alpharma Pharm...
(Date:5/7/2008)... Study to Evaluate Preferred Induction Dosi... -- Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ...icals, a,division of Wyeth (NYSE: WYE ), has comm... trial of TRU-015 in patients with rheumatoid arth...harmaceuticals is developing,TRU-015, SBI-087 and ...
Breaking Medicine Technology:Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4AlphaRx Officers and Directors To Exercise Options Warrants and Retain Shares 8896 1AlphaRx Officers and Directors To Exercise Options Warrants and Retain Shares 8896 2Boston Scientific Announces CE Mark Approval for Next Generation Cardiac Resynchronization Therapy Defibrillator 8892 1Boston Scientific Announces CE Mark Approval for Next Generation Cardiac Resynchronization Therapy Defibrillator 8892 2Boston Scientific Announces CE Mark Approval for Next Generation Cardiac Resynchronization Therapy Defibrillator 8892 3Caraco Pharmaceutical Laboratories Ltd Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets 28R 29 and Zyrtec Hives Relie 8888 1Caraco Pharmaceutical Laboratories Ltd Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets 28R 29 and Zyrtec Hives Relie 8888 2 Diabetes Group Backs Low Carb Diets 8887 1 Diabetes Group Backs Low Carb Diets 8887 2
...ggregate Benefit over Placebo Larger at One Year t... June 11, 2007,/PRNewswire-FirstCall/ -- Medivatio...on over placebo in its double-blind,placebo-contr...,s,disease were statistically significant on all f...every endpoint studied, the benefits,of Dimebon ov...
...W HAVEN, Conn., June 11, 2007 /PRNewswire-FirstCal... presented clinical data in,a poster session at th...tion (EHA) Meeting in Vienna, Austria on its lead ...ingle agent in a,multi-center international Phase ...with acute myelogenous leukemia (AML) or high-risk...
Other Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting 2Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting 3Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting 4
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem.
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem.
Micro Seal Acetabular Liner
Longevity Crosslinked Polyethylene Liners
Medicine Products: